Hydroxyurea

Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.

CAS No. 127-07-1

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
50mg	JPY 22000	国内在庫あり
200mg	JPY 40500	国内在庫あり
1g	JPY 70500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（40）

製品安全説明書

現在のバッチを見る：純度： 100.0%

100.0

Hydroxyurea関連製品

関連ターゲット	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	もっと見る
関連製品	Cisplatin Gemcitabine 5-FU (5-Fluorouracil) Oxaliplatin TMZ(Temozolomide) Gemcitabine HCl Cytarabine Pidnarulex (CX-5461) Fludarabine Phosphate Sofosbuvir SCR7 Bendamustine HCl Capecitabine Cytarabine hydrochloride Favipiravir (T-705) m6A (N6-methyladenosine) Clofarabine RK-33 Lomustine Carmofur Ifosfamide Triapine (3-AP) Mercaptopurine (6-MP) B02 BMH-21 YK-4-279 Nelarabine Floxuridine (FUDR) BrdU (Bromodeoxyuridine) Procarbazine HCl Bergapten Chloroambucil Tegafur (FT-207) Cidofovir Azaguanine-8 Halofuginone Adenine HCl Fidaxomicin Mupirocin Mizoribine Cyclocytidine HCl Thymidine Cyclophosphamide Uridine APX-3330 Vidarabine Rifapentine Nedaplatin 6-Thio-dG Flupirtine maleate Carmustine JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin Rimantadine Hydrochloride BC-LI-0186 CRT0044876 PFM01 Adenine ML216 Rifaximin	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

DNA/RNA Synthesisシグナル伝達経路

DNA/RNA Synthesis阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
U373-MAGI	Function assay	500 uM	2 hrs	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas, EC50 = 25.8 μM.	27117260
U373-MAGI	Function assay	0.5 mM	2 hrs	Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C	27117260
U373-MAGI	Function assay	2 mM	6 hrs	Reduction in dATP level in human U373-MAGI cells at 2 mM after 6 hrs by LC-MS/MS analysis	27117260
U373-MAGI	Function assay	0.5 mM	2 hrs	Reduction in dCTP level in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis	27117260
U373-MAGI	Function assay	2 mM	2 hrs	Reduction in dCTP level in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C	27117260
U373-MAGI	Function assay	0.5 mM	2 hrs	Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC	27117260
U373-MAGI	Function assay	2 mM	2 hrs	Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC	27117260
U373-MAGI	Function assay	0.5 mM	2 hrs	Reduction in dCTP level in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC	27117260
U373-MAGI	Function assay	2 mM	2 hrs	Reduction in dCTP level in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC	27117260
U373-MAGI	Antiviral assay	500 uM		Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 500 uM incubated for 4 hrs prior to viral infection measured at 72 hrs post infection by flow cytometric analysis	27117260
P388 leukemic cell	Proliferation assay		24-48 h	Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition, IC50=32 μM	2709372
L1210	Function assay		48 h	Activity against cultured L1210 leukemic cells was determined in vitro, after 48 h of incubation. Compound dose that causes 16 % inhibition was reported, ID16 = 1.99 μM.	6319702
L1210 Leukemia cells	Growth inhibition assay			Concentration required for 50% inhibition of cell growth (L1210 Leukemia), IC50=21.3796 μM	2991520
Burkitt's lymphoma cells	Function assay			Inhibition of [14C]-cytidine incorporation into DNA in Burkitt's lymphoma cells, IC50 = 37.15 μM.	11405653
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
U-2 OS	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. Hydroxyurea is used to treat HIV infection.

Targets

ribonucleoside diphosphate reductase ^[1]

In Vitro
In vitro	hydroxyurea can inhibit HIV-1 replication. In vitro experiments have shown that the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4 mM. Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutants^[1]^[2].hydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasing the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phase^[1].
細胞実験	細胞株	Erythroid cells
	濃度	30 μM
	反応時間	96 h
	実験の流れ	Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro.Treatment of cells performs in primary culture with 30 μM hydroxyurea for 96 hours.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT06171217	Recruiting	Sickle Cell Disease\|Children	Children''s Hospital Medical Center Cincinnati\|National Heart Lung and Blood Institute (NHLBI)	October 27 2023	Phase 2
NCT05909657	Recruiting	Sickle Cell Disease	The University of The West Indies	July 1 2023	--
NCT05548062	Recruiting	Polycythemia Vera	Novartis Pharmaceuticals\|Novartis	March 2 2023	--
NCT05662098	Recruiting	Sickle Cell Disease	Children''s Hospital Medical Center Cincinnati\|Jinja Regional Referral Hospital (JRRH) Sickle Cell Clinic Jinja Uganda	June 16 2022	Early Phase 1
NCT05494541	Completed	Sickle Cell Disease	Novartis Pharmaceuticals\|Novartis	August 30 2021	--

参考
[1] Lori F, et al. Clin Infect Dis. 2000, 30 Suppl 2:S193-7. [2] Zala C, et al. Clin Infect Dis. 2000, Suppl 2:S143-50. [3] Watanapokasin Y, et al. Exp Hematol. 2005, 33(12):1486-92. [4] Boucher PD, et al. Gene Ther. 2002, 9(15):1023-30. + 展開

参考

[4] Boucher PD, et al. Gene Ther. 2002, 9(15):1023-30.

+ 展開

化学情報

分子量	76.05	化学式	CH₄N₂O₂
CAS No.	127-07-1	SDF	Download Hydroxyurea SDFをダウンロードする
Smiles	C(=O)(N)NO
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 15 mg/mL ( (197.23 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 15 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):